Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Promising new approaches.

C A Reasner1

  • 1Texas Diabetes Institute, University of Texas Health Science Center, San Antonio 78229-4493, USA. tjbarries@university-health-sys.com

Diabetes, Obesity & Metabolism
|February 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of cold iodine in patients with Graves' disease: observations from a clinical practice.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2001
Same author

Treatment of type 2 diabetes mellitus: a rational approach based on its pathophysiology.

American family physician·2001
Same author

Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults.

The Journal of clinical investigation·1998
Same author

Endocrine emergencies. Recognizing clues to classic problems.

Postgraduate medicine·1997
Same author

Hepatitis C-associated osteosclerosis after blood transfusion.

The American journal of medicine·1997
Same author

Diabetic nephropathy--can it be prevented?

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·1996
Same journal

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial.

Diabetes, obesity & metabolism·2026
Same journal

Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.

Diabetes, obesity & metabolism·2026
Same journal

First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.

Diabetes, obesity & metabolism·2026
Same journal

Trends in Prevalence of Diabetes, Pre-Diabetes, and Cardiometabolic Risk Factor Control Among U.S. Adults, 2013-2023.

Diabetes, obesity & metabolism·2026
Same journal

Metabolic Risk-Attributable Dementia Burden: A Life-Course and Cautious Attribution Perspective.

Diabetes, obesity & metabolism·2026
Same journal

A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline.

Diabetes, obesity & metabolism·2026
See all related articles

Type 2 diabetes management involves diet, exercise, and various medications. New drugs like thiazolidinediones improve insulin resistance, while combination therapies offer synergistic benefits for better glycemic control.

Area of Science:

  • Endocrinology and Pharmacology
  • Metabolic Diseases
  • Drug Development

Background:

  • Type 2 diabetes mellitus results from insulin resistance and beta-cell dysfunction.
  • Early stages may be managed with diet and exercise, but pharmacological interventions are crucial for many.
  • Weight reduction and pharmacological weight loss agents are explored for managing type 2 diabetes in obese patients.

Purpose of the Study:

  • To review current and emerging pharmacological approaches for type 2 diabetes management.
  • To discuss the role of weight-reducing agents and novel antidiabetic drugs.
  • To highlight the development and therapeutic potential of thiazolidinediones.

Main Methods:

  • Review of pharmacological agents for obesity and type 2 diabetes.

Related Experiment Videos

  • Analysis of insulin secretagogues, amylin analogues, and glucagon-like peptides.
  • Examination of thiazolidinediones (troglitazone, rosiglitazone, pioglitazone) and their mechanisms.

    • Main Results:

    • Sibutramine shows promise for obesity but is less effective in diabetic patients.
    • Repaglinide effectively reduces postprandial hyperglycemia.
    • Thiazolidinediones improve insulin resistance; troglitazone has safety concerns (hepatotoxicity), while rosiglitazone and pioglitazone show promise.

    Conclusions:

    • Combination therapy is essential for type 2 diabetes management after monotherapy failure.
    • Novel agents and established drugs like thiazolidinediones offer improved glycemic control.
    • Ongoing research focuses on developing safer and more effective treatments for type 2 diabetes.